Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

3 Pharma Stocks Poised for Big Returns This Summer

The pharmaceutical industry is expected to grow rapidly due to the ever-rising healthcare needs and the incorporation of cutting-edge technologies into drug manufacturing. Hence, pharma stocks Eli Lilly (LLY), Green Thumb Industries (GTBIF), and Supernus Pharmaceuticals (SUPN) might be worth buying for returns this summer. Read more….

StockNews.com

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

Investors Business Daily

Do Wall Street Analysts Like Eli Lilly Stock?

Eli Lilly stock has outperformed the broader market over the past year, and Wall Street analysts remain optimistic about the stock’s prospect.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Costco, Eli Lilly Near New Highs; That Doesn't Scare Mutual Funds

Costco stock is in a buy zone ahead of the earnings report Thursday. Mutual funds like this stock and a few others.

Investors Business Daily

Dow Jones Futures Fall, But Nvidia Leads Techs Higher; 7 Stocks Near Buy Points

The market rally had a mixed week as breadth narrowed. Microsoft and Merck led stocks near buy points. Here's what to do.

Investors Business Daily

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Which Pharma Stock Is Driving Long-Term 2024 Profits?

The pharmaceutical market is poised for rapid expansion due to rising global medical needs and increasing integration of technologies in drug discovery and development. Amid this, let’s analyze Eli Lilly (LLY) and Novo Nordisk (NVO) to determine which pharma stock will drive long-term profits in 2024. Read more to find…

StockNews.com

Eight Massive ETFs With Billions In Assets Are Beating The S&P 500

You don't need to gamble on tiny ETFs with scant assets to beat the S&P 500. Turns out you can do it just fine with massive ones.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

It's Time for Over-the-Counter Ozempic

There's an easy way to lower the cost of next-generation weight-loss drugs.

Reason

Dow Jones Futures Fall As Target Tumbles; Nvidia Looms Over Stock Market

The Nasdaq hit a new high Tuesday but Target tumbled early Wednesday. Will Nvidia earnings tonight meet lofty hopes?

Investors Business Daily

IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High

Eli Lilly is Tuesday's IBD Stock Of The Day after shares surged into a buy zone, again, on promising test results for a Crohn's treatment.

Investors Business Daily

Magnificent Seven? Just Two Members Clear This Bar

Ultimately, earnings drive share prices. Only two Magnificent Seven stocks, and a third megacap, meet this triple-25% growth standard.

Investors Business Daily

Dow Jones Futures Rise On Cisco, Walmart After Market Rally Hits Highs, Nvidia Breaks Out

Futures rose on Cisco and Walmart. On Wednesday, the Dow, S&P 500 and Nasdaq hit record highs, with Nvidia leading new buys.

Investors Business Daily

1 'Strong Buy' Dividend Stock to Buy and Hold

Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects.

Barchart

How A Top Fund Beats The Market By Owning Future Leaders

Julianne McHugh, lead manager of best mutual fund BNY Mellon Large Cap Securities, isn't interested in blue-chip stars of yesteryear.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Mutual Funds Can't Get Enough Amazon, Broadcom

Amazon stock climbs back near highs and is a mutual funds favorite. Shares gained more than 23% this year. Broadcom stock tests a key level.

StockNews.com

Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

Al Jazeera

What is behind the insulin shortage in the US?

Pharma companies are slashing insulin production in favour of more lucrative weight-loss drugs.

The Guardian - UK

Danish firm behind weight-loss drug Wegovy raises profit forecast to £15.3bn

Novo Nordisk, which is now Europe’s most valuable company, also reports strong sales of diabetes drug Ozempic

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Fall As Fed Looms; Amazon Rises As AMD, Super Micro Plunge

The market rally stumbled ahead of the Fed meeting. Amazon rose on earnings while AI plays Super Micro and AMD plunged.

Investors Business Daily

IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views

Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.

Barchart

Stocks Sink on Concern the Fed Will Keep Interest Rates Higher for Longer

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -1.57%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.92%. US stock indexes Tuesday finished sharply lower. Signs of persistent wage pressure pushed bond...

Kiplinger

Stock Market Today: Stocks Sell Off Ahead of Fed Decision

Stocks sold off sharply Tuesday as anxiety set in ahead of Wednesday's policy statement from the Federal Reserve.

Investors Business Daily

Dow Jones Futures Rise: Nvidia Leads New Buys; Tesla Runs Past Resistance On Elon Musk Move

Nvidia and several other leaders flashed buy signals as the market roared. Investors should take advantage, but it's a jungle out there.

Investors Business Daily

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

Barchart

Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.

1 … 16 17 18 19

People

Mangeet Kaur BounsMangeet

Margaret Kaczor Andrew

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations